A majority of proliferating T cells in cutaneous malignant T cell lymphomas may lack the high affinity IL-2 receptor (CD25)

Abstract

IL-2 is a major growth factor for all T-cell subsets acting via a specific membrane receptor. To investigate its role in the pathogenesis of cutaneous T-cell lymphomas (CTCLs), we analysed the expression of high-affinity IL-2 receptors (IL-2Rs) on proliferating cells in these disorders. We showed by immunohistochemical double staining that most cycling cells do not express high-affinity IL-2Rs. Four T-cell lines were established from patients with CTCLs. Two lines required both IL-2 and IL-4 for growth, one line required IL-2 and one line IL-4 alone. The last of these lacked expression of the IL-2R alpha-chain. Thus, IL-2 may not be the only, or the most important, growth stimulus in CTCLs and reactive skin infiltrates. T helper cells, which dominated the infiltrate, might represent TH2 cells.

Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.

“…It appears, therefore, that low-grade T-cell lymphomas of the skin may still be dependent on autocrine or paracrine cytokines for their growth, whereas the high-grade tumors may become progressively independent of these factors. Evidence that SzS cells appear to produce cytokines of the Th2 type such as IL-4 (51), and that ALCL cells do not produce IL-4 or IL-2 (42,52,53), is consistent with such an explanation. Furthermore, the 2A and 2B cell lines studied here express less IL-2R than the PB-1 line (Fig.…”

Cutaneous Hematopathology

“…These cells, usually medium or large in size, also express activation antigen CD30, a member of the tumor necrosis family (az-Cascajo 2001 ; Cepeda et al 2003 ;Droc et al 2007 ;Eckert et al 1989 ;Edinger et al 2009 ;Gallardo et al 2002 ;Gniadecki and Rossen 2003 ;Kadin 2006 ;Kempf et al 2012 ;Kikuchi et al 1992 ). Similarly, the interleukin-2 family of receptors (Boehncke et al 1993 ;Jakob et al 1996 ; Kelley and Parker 2010 ) is noted to be present. Both antigens are seen in certain Tand B-cell lymphomas of the skin.…”

IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future

“…Sezary Syndrome (SS) [44,49] Hodgkin's Disease (HD) [50,51] Non-Hodgkin's Lymphoma (NHL) [41,51,52] T and B cell leukemias and lymphomas [41,45,50,51,[53][54][55][56] Activated T cell diseases and disorders [39,[57][58][59] Allograft rejection (solid organ) [60][61][62] GvHD (bone marrow) [63,64] Type 1 Diabetes (T1D) [65][66][67] Psoriasis [68][69][70] Uveitis [71][72][73] Rheumatoid arthritis [74,75] Crohn's Disease, Colitis (IBD) [76][77][78] …”